Health inequality in liver diseases including age, gender, ethnicity and socioeconomic status has been increasingly recognised and potentially hinder hepatitis elimination. Health inequality has significant impact to evaluate the impact diagnostic and treatment uptake rates of chronic viral hepatitis on risk of hepatocellular carcinoma (HCC), hepatic event and liver-related death in patients with chronic hepatitis B and/or C. To overcome the limitation of small prospective cohort study of limited recruitment period, retrieving information from the Clinical Data Analysis and Reporting System (CDARS) from Hospital Authority (HA) will be one of the best way to answer these questions.
Study Type
OBSERVATIONAL
Enrollment
100,000
Safety
Time from diagnosis of hepatitis to treatment.
Time frame: From 1 January 2000 to 31 March 2024
Safety
The composite endpoints of recurrence of hepatic events (e.g. HCC hepatic coma, portal hypertension, variceal bleeding, hepatorenal syndrome).
Time frame: From 1 January 2000 to 31 March 2024
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.